Shopping Cart 0
Cart Subtotal
USD 0

Targovax ASA (TRVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company's lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02, TG03, ONCOS-402, ONCOS-802 and ONCOS-902 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient's immune system to target cancer, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company operates through its offices in Norway and Finland. Targovax is headquartered in Oslo, Norway.

Targovax ASA (TRVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Targovax ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Targovax ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Targovax ASA, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Targovax Raises USD 1.3 Million In Venture Financing 11

Targovax Raises USD 2.2 Million In Series A Financing 12

Targovax Raises Additional USD 1 Million In Venture Financing 13

Partnerships 14

Targovax Enters into Agreement with Sotio 14

Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 15

Merger 16

Oncos Therapeutics Completes Merger with Targovax 16

Equity Offering 17

Targovax Raises USD0.8 Million in Rights Offering of Shares 17

Targovax Raises USD23.6 Million in Private Placement of Shares 18

Targovax Raises USD0.5 Million in IPO 20

Targovax Raises USD13.3 Million in Private Placement of Shares 21

Targovax Raises USD26 Million in Private Placement of Shares 22

Targovax Raises USD11.6 Million through Shares Issue 24

Targovax ASA-Key Competitors 25

Targovax ASA-Key Employees 26

Targovax ASA-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Financial Announcements 28

Feb 15, 2018: Targovax: Fourth quarter and full year 2017 results 28

Apr 25, 2017: Targovax:First quarter 2017 results 30

Feb 16, 2017: Targovax: Fourth quarter and full year 2016 results 31

Corporate Communications 33

Sep 13, 2018: Targovax strengthens management team with the appointment of Torbjorn Furuseth as CFO; Erik Digman Wiklund to become CBO 33

Apr 12, 2018: Targovax strengthens Board of Directors with the appointment of Catherine Wheeler 34

Jan 08, 2018: Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer 35

Nov 30, 2017: Targovax: New Member of the Board of Directors-Nov. 30, 2017 36

Mar 22, 2017: Targovax: The board of directors of Oslo Stock Exchange approves transfer of Targovax to the main list 37

Jan 05, 2017: Targovax announces appointment of Erik Digman Wiklund as CFO 38

Other Significant Developments 39

Aug 23, 2018: Targovax: Second quarter and first half year 2018 results 39

Jun 11, 2018: Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program 40

May 03, 2018: Targovax: First quarter 2018 results 41

Nov 02, 2017: Targovax: Third quarter 2017 results 42

Aug 24, 2017: Targovax: Second quarter and first half 2017 results 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Targovax ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Targovax ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Targovax ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Targovax ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Targovax ASA, Deals By Therapy Area, 2012 to YTD 2018 9

Targovax ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Targovax Raises USD 1.3 Million In Venture Financing 11

Targovax Raises USD 2.2 Million In Series A Financing 12

Targovax Raises Additional USD 1 Million In Venture Financing 13

Targovax Enters into Agreement with Sotio 14

Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 15

Oncos Therapeutics Completes Merger with Targovax 16

Targovax Raises USD0.8 Million in Rights Offering of Shares 17

Targovax Raises USD23.6 Million in Private Placement of Shares 18

Targovax Raises USD0.5 Million in IPO 20

Targovax Raises USD13.3 Million in Private Placement of Shares 21

Targovax Raises USD26 Million in Private Placement of Shares 22

Targovax Raises USD11.6 Million through Shares Issue 24

Targovax ASA, Key Competitors 25

Targovax ASA, Key Employees 26

Targovax ASA, Other Locations 27

Targovax ASA, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Targovax ASA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.